Genedrive has successfully completed an oversubscribed US$10 million equity fundraise
Genedrive plc has completed an equity fundraising to support the rapid development of the Genedrive® SARS-CoV-2 assays, fund the scale-up of the Genedrive-96-SARS-CoV-2 test including build-up of inventory for an initial period, fund product development, commercialization and general corporate purposes.
Genedrive is a molecular diagnostics company developing and commercializing a low-cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The company is passionate about the opportunity to not only build a sustainable business around molecular diagnostics, but to play an important role in the diagnostic and treatment challenges presented by global health issues.
Oaklins Cavendish’s sister firm finnCap, based in the UK, advised Genedrive plc on its oversubscribed equity fundraising.
Talk to the deal team
Related deals
Generali has expanded its footprint in Bulgaria by acquiring one of the top health insurers on the market
Doverie United Holding has successfully completed the sale of United Health Insurance Fund Doverie (Doverie) to Generali CEE Holding.
Learn moreCustomerXPs Software (Clari5) has been acquired by Perfios Software Solutions
Bengaluru-based SaaS firm Perfios Software Solutions Private Ltd. has acquired 100% of the equity shares in the fraud-detection platform CustomerXPs Software Private Ltd. (Clari5) for an undisclosed amount, enhancing its anti-financial crime management suite for financial institutions.
Learn moreRC Fornax plc has completed a successful AIM admission and fundraising
RC Fornax plc has completed its AIM admission and fundraising. As a UK-based, veteran-founded engineering consultancy providing critical solutions to the defense sector, RC Fornax’s successful AIM admission and US$7.7 million (£6.15 million) fundraising represent a significant milestone in its growth.
Learn more